1. A 44-year-old man with acute myeloid leukemia is on Day 18 of induction chemotherapy. He has been receiving fluconazole 400 mg daily as antifungal prophylaxis since Day 1. He develops persistent fevers despite 96 hours of broad-spectrum antibacterial therapy. Blood cultures are negative. A chest CT shows no pulmonary infiltrates. He is hemodynamically stable but remains profoundly neutropenic (ANC 80 cells/mm³). Empirical antifungal therapy is being considered. Which choice and rationale is most appropriate?
A) Continue fluconazole prophylaxis at the current dose and add micafungin only if blood cultures become positive for a fungal organism, since prophylaxis failure is unlikely in a hemodynamically stable patient
B) Switch to fluconazole 800 mg daily (dose escalation); the higher dose overcomes prophylaxis failure by achieving plasma concentrations sufficient to cover fluconazole-intermediate Candida glabrata without requiring a drug class change
C) Start liposomal amphotericin B (L-AmB) 3 mg/kg IV daily as the only appropriate agent for empirical antifungal therapy in neutropenic patients; echinocandins are not guideline-supported for this indication
D) Start an echinocandin (caspofungin, micafungin, or anidulafungin); prior fluconazole prophylaxis is a specific indication to choose an echinocandin over fluconazole for empirical therapy in febrile neutropenia because azole breakthrough infections are enriched for fluconazole-resistant organisms, particularly Candida glabrata
E) Start voriconazole 6 mg/kg IV twice on Day 1 then 4 mg/kg IV twice daily; voriconazole is the preferred empirical agent in neutropenic patients because of its superior Aspergillus coverage compared to echinocandins and its proven efficacy as empirical therapy in febrile neutropenia trials
ANSWER: D
Rationale:
Option D is correct. In febrile neutropenic patients who have received prior azole prophylaxis, an echinocandin is the preferred empirical antifungal rather than fluconazole. The pharmacological rationale is that azole prophylaxis selects for azole-resistant organisms; any breakthrough fungal infection in this setting is disproportionately likely to be caused by fluconazole-resistant or fluconazole-intermediate Candida glabrata, inherently fluconazole-resistant Candida krusei, or an azole-resistant mold. Continuing or escalating fluconazole in a patient with clinical evidence of prophylaxis failure treats the least likely cause. Echinocandins cover the major Candida species including fluconazole-resistant C. glabrata and C. krusei and are guideline-supported for empirical therapy in febrile neutropenia. All three echinocandins are appropriate choices in this setting.
Option A: Option A is incorrect: clinical evidence of prophylaxis failure (persistent fever despite antibacterials in a neutropenic patient) is the indication for empirical antifungal escalation; waiting for positive blood cultures before acting is not appropriate management in febrile neutropenia.
Option B: Option B is incorrect: dose escalation of fluconazole does not reliably overcome resistance in fluconazole-resistant or intermediate organisms; the breakthrough risk is due to resistant organisms selected by prophylaxis, not to inadequate fluconazole exposure.
Option C: Option C is incorrect: L-AmB is an appropriate alternative for empirical therapy in febrile neutropenia but is not the only guideline-supported option; echinocandins are also guideline-supported and are preferred by many clinicians given their superior tolerability.
Option E: Option E is incorrect: while voriconazole has excellent Aspergillus coverage, it is not the preferred empirical agent in patients with prior azole prophylaxis — the concern about selecting for resistant Candida applies to all azole class members, and voriconazole is not consistently guideline-preferred over echinocandins for empirical candidemia coverage in this setting.
2. A 52-year-old liver transplant recipient maintained on cyclosporine 150 mg twice daily and tacrolimus 2 mg twice daily develops Candida albicans candidemia on post-transplant Day 21. The hepatology team asks for echinocandin selection guidance, specifically whether caspofungin is appropriate. Which analysis and recommendation is correct?
A) Caspofungin is the preferred choice because it has the most extensive published efficacy data in transplant patients and its interactions with cyclosporine and tacrolimus are managed simply by halving both immunosuppressant doses on Day 1 of caspofungin
B) Micafungin or anidulafungin is preferred over caspofungin; caspofungin's interaction with cyclosporine increases caspofungin AUC (area under the concentration-time curve) by approximately 35% with associated ALT (alanine aminotransferase) elevation risk, and caspofungin simultaneously reduces tacrolimus concentrations by approximately 20% requiring tacrolimus TDM (therapeutic drug monitoring) — two simultaneous interactions in opposite directions make caspofungin the most pharmacokinetically complex choice in this patient
C) Caspofungin is acceptable provided the cyclosporine dose is reduced by 35% before initiating caspofungin; this prevents the cyclosporine-mediated increase in caspofungin AUC and eliminates the hepatotoxicity risk without needing to change the echinocandin
D) Micafungin is contraindicated in liver transplant recipients because post-transplant hepatic regeneration upregulates arylsulfatase activity, causing micafungin to be metabolized too rapidly for therapeutic concentrations to be maintained; caspofungin must be used despite its interaction profile
E) Anidulafungin is contraindicated in patients on tacrolimus because its ethanol vehicle inhibits tacrolimus metabolism by CYP3A4 (cytochrome P450 3A4), producing dangerously supratherapeutic tacrolimus concentrations; micafungin is the only safe echinocandin in this specific combination
ANSWER: B
Rationale:
Option B is correct. This patient presents both transplant immunosuppressants that interact with caspofungin, and the interactions are mechanistically distinct and directionally opposite. Cyclosporine inhibits hepatic OATP1B1/OATP1B3 uptake transporters, increasing caspofungin AUC by approximately 35% with associated transient ALT elevations — here the drug affected is caspofungin (it accumulates). Simultaneously, caspofungin reduces tacrolimus plasma concentrations by approximately 20% through an uncertain transporter-mediated mechanism — here the drug affected is tacrolimus (it is depleted). The net clinical picture is: caspofungin overexposure plus tacrolimus underexposure plus hepatotoxicity risk, all in a patient whose liver has just undergone transplantation. Both micafungin and anidulafungin avoid these interactions: micafungin does not significantly affect cyclosporine or tacrolimus concentrations and is not significantly affected by them; anidulafungin's non-enzymatic elimination is unaffected by any calcineurin inhibitor. Either is preferred in transplant patients on calcineurin inhibitors.
Option A: Option A is incorrect: halving both immunosuppressant doses is not the approved management for these interactions and would risk acute rejection from subtherapeutic tacrolimus and cyclosporine; the appropriate response is to select a different echinocandin.
Option C: Option C is incorrect: reducing cyclosporine to prevent it from increasing caspofungin AUC inverts the management — cyclosporine should not be reduced for the purpose of normalizing caspofungin exposure, and doing so risks acute rejection; the correct approach is to select a different echinocandin.
Option D: Option D is incorrect: post-transplant hepatic regeneration does not upregulate arylsulfatase sufficiently to prevent therapeutic micafungin concentrations; this mechanism is not pharmacologically established, and micafungin is used in transplant patients without this concern.
Option E: Option E is incorrect: anidulafungin's ethanol vehicle is modest in quantity and does not produce clinically meaningful CYP3A4 inhibition; no interaction between anidulafungin's vehicle and tacrolimus metabolism has been established.
3. A 61-year-old woman with acute leukemia has been receiving caspofungin for three weeks for persistent Candida glabrata candidemia following induction chemotherapy. A repeat blood culture grows C. glabrata with a caspofungin MIC of 8 mg/L (above the CLSI susceptibility breakpoint). Molecular testing confirms an FKS2 hot spot 1 mutation. The team considers switching to anidulafungin at a higher dose of 200 mg daily as definitive therapy. Which response most accurately evaluates this plan?
A) Switching to anidulafungin will not be effective; FKS2 hot spot mutations reduce the binding affinity of all three echinocandins at the shared Fks binding site, conferring class-wide cross-resistance — neither anidulafungin nor micafungin will overcome this resistance, and liposomal amphotericin B (L-AmB) is the appropriate alternative pending azole susceptibility data
B) Switching to anidulafungin at 200 mg daily is appropriate; anidulafungin's longer half-life produces a higher AUC (area under the concentration-time curve) than caspofungin at equivalent doses, achieving pharmacodynamic target attainment against FKS2-mutant isolates at this elevated dose
C) Switching to micafungin is appropriate because FKS2 mutations in C. glabrata specifically impair caspofungin binding through a steric interaction with its N-acetyl side chain; micafungin lacks this side chain and therefore retains full activity against FKS2-mutant isolates
D) Switching to anidulafungin is appropriate because anidulafungin targets a different hot spot region (HS2) than caspofungin (HS1); FKS2 mutations at HS1 do not affect anidulafungin binding geometry, preserving its activity against this isolate
E) Continuing caspofungin at an escalated dose of 150 mg daily is more appropriate than switching agents; supramaximal caspofungin dosing overcomes FKS2 resistance by saturating the mutant Fks enzyme with drug concentrations far exceeding the elevated MIC
ANSWER: A
Rationale:
Option A is correct. FKS2 hot spot mutations in Candida glabrata alter the conformational geometry of the Fks glucan synthase subunit at the shared echinocandin binding site — the same site targeted by all three echinocandins. Because caspofungin, micafungin, and anidulafungin bind to the same HS1 and HS2 regions of the Fks subunit, a mutation at these positions confers cross-resistance to the entire class regardless of the specific lipopeptide structure of each agent. The several-orders-of-magnitude reduction in binding affinity caused by FKS hot spot mutations is not overcome by increased drug exposure at clinically achievable doses. Switching within the echinocandin class is therefore pharmacologically ineffective. Liposomal amphotericin B (L-AmB) is the standard alternative for echinocandin-resistant C. glabrata candidemia. Azole susceptibility testing should also be performed because azole resistance may coexist with echinocandin resistance in some C. glabrata isolates, particularly those with prolonged echinocandin exposure and multiple prior antifungal courses.
Option B: Option B is incorrect: anidulafungin's higher AUC does not overcome the several-orders-of-magnitude reduction in binding affinity caused by FKS mutations; pharmacodynamic target attainment against a genuinely resistant isolate cannot be achieved through dose escalation alone.
Option C: Option C is incorrect: FKS2 mutations in C. glabrata are not agent-specific or structure-specific; the N-acetyl side chain distinction between echinocandins is not the basis of resistance, and micafungin does not retain selective activity against FKS2-mutant isolates.
Option D: Option D is incorrect: all three echinocandins bind to both HS1 and HS2 regions of the Fks subunit; there is no agent-specific segregation of binding to HS1 versus HS2, and the premise of this option is pharmacologically incorrect.
Option E: Option E is incorrect: supramaximal caspofungin dosing does not overcome FKS mutation-mediated resistance; the mutation reduces binding affinity by orders of magnitude, and dose escalation to 150 mg — while off-label — does not achieve a pharmacodynamic exposure sufficient to overcome this level of resistance.
4. A 58-year-old man in the medical ICU has decompensated alcoholic cirrhosis (Child-Pugh score 9), oliguric acute kidney injury requiring continuous venovenous hemofiltration (CVVH), and is receiving rifampin as part of treatment for culture-confirmed pulmonary tuberculosis. Blood cultures grow Candida tropicalis. The critical care team asks the pharmacist to justify echinocandin selection from first principles. Which agent and reasoning chain is correct?
A) Caspofungin 35 mg IV once daily (hepatic dose adjustment) is appropriate; the rifampin interaction is clinically negligible in a patient with severely impaired hepatic drug transport because the liver is already dysfunctional and cannot upregulate transporters in response to rifampin induction
B) Micafungin 100 mg IV once daily is appropriate; its arylsulfatase-COMT elimination is independent of CYP enzymes and is sufficiently unaffected by rifampin induction to avoid any dose modification, and CVVH does not remove micafungin because of its high protein binding
C) Caspofungin 70 mg IV once daily (rifampin escalation) is appropriate; the hepatic impairment dose adjustment is overridden by the inducer effect of rifampin, and CVVH removes caspofungin sufficiently to negate any drug accumulation concerns from hepatic impairment
D) Micafungin 200 mg IV once daily is appropriate; doubling the dose preemptively compensates for the modest CYP3A4 induction by rifampin on micafungin's minor metabolic pathway, and the elevated dose is safe because micafungin is entirely non-nephrotoxic
E) Anidulafungin 200 mg loading dose then 100 mg IV once daily is appropriate; its non-enzymatic elimination is completely unaffected by rifampin induction, requires no dose adjustment for Child-Pugh 9 hepatic failure or for CVVH, and has no pharmacokinetic interaction with any co-administered drug — making it the only echinocandin that addresses all three pharmacokinetic challenges in this patient without modification
ANSWER: E
Rationale:
Option E is correct. Systematically applying each pharmacokinetic challenge to the three echinocandins: Rifampin co-administration — caspofungin requires escalation to 70 mg daily due to ~30% AUC reduction from transporter induction; micafungin's minor CYP3A4 pathway is subject to some induction but not to a degree requiring approved dose modification; anidulafungin's non-enzymatic chemical degradation is entirely unaffected by any enzyme or transporter induction. Child-Pugh 9 hepatic impairment — caspofungin requires maintenance dose reduction to 35 mg daily at Child-Pugh 7 to 9, creating a conflict with the simultaneous rifampin escalation requirement; micafungin is not well studied in severe hepatic impairment and should be used with caution above Child-Pugh 9; anidulafungin requires no dose adjustment for any degree of hepatic impairment because its degradation is non-enzymatic and hepatic function is irrelevant. CVVH — anidulafungin is highly protein-bound (>99%) and has a large molecular weight; it is not meaningfully removed by CVVH and requires no supplemental dosing; caspofungin and micafungin are similarly not significantly removed by CVVH. Anidulafungin at standard doses is the only agent that resolves all three challenges simultaneously without dose modification or competing adjustments.
Option A: Option A is incorrect: severe hepatic dysfunction does not prevent rifampin-mediated transporter induction because transporter upregulation at the transcriptional level remains partially functional even in cirrhosis; assuming the interaction is negligible in this patient is pharmacologically unsound.
Option B: Option B is incorrect: while micafungin is a reasonable consideration, it lacks robust safety data in Child-Pugh 9 to 11 hepatic impairment, and the reasoning ignores this gap; anidulafungin provides more complete pharmacokinetic certainty.
Option C: Option C is incorrect: caspofungin is caught between two competing adjustments — rifampin requires 70 mg and hepatic impairment requires 35 mg; these cannot be resolved to a single approved dose, and CVVH removal of caspofungin is not a basis for waiving the hepatic dose reduction.
Option D: Option D is incorrect: doubling micafungin to 200 mg daily for rifampin co-administration is not an approved or studied strategy; this represents an unapproved dose escalation without pharmacokinetic justification and exposes the patient to unknown toxicity risk.
5. A 38-year-old woman with aplastic anemia and prolonged neutropenia is being treated with caspofungin for Candida albicans candidemia. After eight days of therapy, blood cultures have been negative for five days and she is clinically improving. She reports new floaters and blurred vision in her right eye for two days. Ophthalmologic examination reveals creamy white chorioretinal lesions with overlying vitreous haze. Repeat blood cultures are negative. The ophthalmologist confirms Candida endophthalmitis with vitreous involvement. Which pharmacological principle explains why caspofungin is inadequate for treating this complication, and what is the most appropriate management change?
A) Caspofungin is inadequate because it is fungistatic rather than fungicidal against Candida in ocular tissue, requiring a switch to an agent with fungicidal activity at vitreous drug concentrations; liposomal amphotericin B achieves fungicidal vitreous concentrations and should replace caspofungin
B) Caspofungin is inadequate because Candida albicans in the vitreous acquires echinocandin resistance through FKS mutations under the selective pressure of systemic therapy; the ocular isolate should be sent for FKS testing and voriconazole initiated empirically pending results
C) Echinocandins as a class distribute poorly into the vitreous humor regardless of dose or agent; this is a pharmacokinetic class limitation rather than a dose-dependent failure — vitreous drug concentrations achieved by any echinocandin are insufficient for treating Candida endophthalmitis; transition to fluconazole, which achieves therapeutic vitreous concentrations, is indicated, with consideration of intravitreal antifungal injection for severe vitreous involvement
D) Caspofungin is adequate for the systemic infection but inadequate for vitreous involvement because its high protein binding prevents any free drug from crossing the blood-retinal barrier; escalating to anidulafungin — which has lower protein binding — achieves higher free drug concentrations in the vitreous and is the preferred switch
E) Caspofungin is inadequate because the recommended duration for Candida endophthalmitis is six weeks of systemic therapy, which requires switching to an oral agent for outpatient completion; oral micafungin is the preferred step-down for Candida endophthalmitis
ANSWER: C
Rationale:
Option C is correct. Poor vitreous and central nervous system penetration is a class property of all three echinocandins. The pharmacokinetic basis is structural: echinocandins are large (>1,000 Da), highly protein-bound (>97%) lipopeptides. The blood-retinal barrier restricts passage of large, protein-bound molecules, and the drug concentrations achieved in the vitreous following systemic echinocandin administration are not sufficient for treating Candida endophthalmitis. This limitation is not dose-dependent — increasing the caspofungin dose or switching to anidulafungin or micafungin does not overcome the class penetration barrier. Fluconazole achieves good ocular penetration and is the preferred systemic agent for Candida endophthalmitis caused by susceptible organisms; voriconazole is an alternative, particularly for fluconazole-resistant species. In cases with dense vitreous involvement (as in this patient), intravitreal antifungal injection (amphotericin B deoxycholate or voriconazole) by an ophthalmologist may be required as adjunctive therapy.
Option A: Option A is incorrect: echinocandins are fungicidal against Candida, not fungistatic; the problem is pharmacokinetic (poor penetration), not a wrong activity type; and L-AmB also penetrates the vitreous poorly, making it no better than caspofungin for this indication.
Option B: Option B is incorrect: de novo FKS mutation acquisition in the vitreous creating a distinct resistant ocular isolate while blood cultures remain negative is not a plausible explanation for treatment failure after only eight days of therapy; the pharmacokinetic barrier is the correct explanation.
Option D: Option D is incorrect: all three echinocandins have very similar and very high protein binding (all >97%); there is no meaningful free-drug advantage with anidulafungin, and this distinction does not explain or resolve the class-wide vitreous penetration limitation.
Option E: Option E is incorrect: oral micafungin does not exist — echinocandins are not orally bioavailable and cannot be used for outpatient step-down oral therapy.
6. A 67-year-old man undergoes coronary artery bypass grafting complicated by mediastinitis requiring prolonged ICU stay with multiple central venous catheters. On post-operative Day 19, blood cultures drawn from a central line and a peripheral site both grow Candida parapsilosis. Susceptibility testing returns: fluconazole MIC 1 mg/L (susceptible), micafungin MIC 2 mg/L (at the upper boundary of susceptible range). The infected central line has been removed. The patient is clinically improving — afebrile for 48 hours, hemodynamically stable, tolerating enteral nutrition. A follow-up blood culture at 72 hours is negative. Which antifungal strategy is most pharmacologically appropriate as definitive therapy?
A) Transition to fluconazole 400 mg daily via enteral tube; C. parapsilosis has intrinsically elevated echinocandin MICs reflecting species-level reduced glucan synthase inhibitor susceptibility — not acquired FKS resistance — and when fluconazole susceptibility is confirmed, fluconazole is the preferred definitive agent; source control has been achieved with catheter removal
B) Continue micafungin 100 mg IV daily for a total of 14 days from today; echinocandins are guideline-preferred for all Candida species including C. parapsilosis regardless of MIC values within the susceptible range, and the elevated MIC does not warrant a drug class change
C) Escalate to anidulafungin 200 mg loading dose then 200 mg IV daily (double maintenance) to overcome the intrinsically elevated C. parapsilosis echinocandin MIC; the higher daily AUC (area under the concentration-time curve) provides sufficient pharmacodynamic target attainment against this species
D) Add fluconazole 400 mg daily to the current micafungin without discontinuing the echinocandin; dual antifungal therapy is required for C. parapsilosis candidemia when echinocandin MICs are at the upper susceptible boundary, as monotherapy with either agent alone carries unacceptable failure risk
E) Perform ophthalmologic evaluation and echocardiogram before making any antifungal decision; post-cardiac surgery patients with Candida parapsilosis candidemia have an absolute requirement for deep-seated infection exclusion completed in full before any step-down or agent change is clinically permissible
ANSWER: A
Rationale:
Option A is correct. Three pharmacological and clinical principles converge in this case. First, C. parapsilosis exhibits intrinsically elevated echinocandin MICs compared to C. albicans, C. tropicalis, and C. krusei — this is a species-level pharmacological characteristic reflecting reduced glucan synthase inhibitor susceptibility, not an acquired FKS hot spot mutation. Second, the isolate is confirmed fluconazole-susceptible (MIC 1 mg/L, well within the susceptible range), making fluconazole pharmacologically sound as definitive therapy. Third, source control has been achieved with catheter removal, eliminating the biofilm nidus. Current IDSA guidelines for candidiasis support fluconazole as the preferred definitive agent for C. parapsilosis when susceptibility is confirmed. The patient meets clinical criteria for step-down: afebrile, hemodynamically stable, tolerating enteral nutrition, and with a negative follow-up culture.
Option B: Option B is incorrect: while echinocandins are guideline-preferred for empirical and initial therapy of most Candida candidemia, the C. parapsilosis-specific guidance recommends fluconazole as the preferred definitive agent when susceptibility is confirmed, precisely because of the intrinsically elevated echinocandin MIC; continuing micafungin at this point is not the optimal management.
Option C: Option C is incorrect: doubling the anidulafungin maintenance dose to 200 mg daily is not an approved strategy, lacks pharmacokinetic justification, and fails to address the underlying reason fluconazole is preferred — the species-level MIC characteristic favors switching drug class, not escalating within it.
Option D: Option D is incorrect: dual antifungal therapy is not recommended for C. parapsilosis candidemia; the correct approach is appropriate monotherapy with the preferred agent, not combination therapy.
Option E: Option E is incorrect: while routine ophthalmologic evaluation and echocardiogram are recommended for candidemia work-up, these evaluations do not create an absolute mandatory delay before initiating a clinically indicated antifungal transition; if evaluation is pending, it proceeds concurrently with appropriate antifungal management.
7. A 55-year-old woman with type 2 diabetes and a recent small bowel resection for ischemic bowel has been on micafungin for five days for Candida albicans candidemia. Today: temperature 37.1°C, blood pressure 118/74 mmHg, tolerating sips of clear liquids by mouth. Susceptibility testing confirms fluconazole MIC 0.25 mg/L (susceptible). Follow-up blood cultures drawn at Day 3 are negative. A transthoracic echocardiogram shows no vegetations. Dilated ophthalmologic examination is normal. WBC is recovering (ANC 1,800 cells/mm³). CT abdomen shows a 2.1 cm fluid collection adjacent to the anastomotic site with rim enhancement, aspirated under CT guidance today — Gram stain shows yeast, culture pending. Which statement about oral step-down to fluconazole is most accurate for this patient?
A) Step-down to oral fluconazole is appropriate now; all major criteria are met — fluconazole susceptibility is confirmed, blood cultures are negative, endocarditis and ocular infection have been excluded, and neutropenia has resolved
B) Step-down is appropriate only after the patient tolerates full oral diet, not just sips of liquids; adequate oral absorption of fluconazole requires solid food to slow gastric emptying and maximize intestinal drug contact time
C) Step-down is not yet appropriate; fluconazole absorption is unreliable in patients with prior bowel resection because the proximal small bowel is the primary site of oral fluconazole absorption, and adequate systemic bioavailability cannot be assumed after this patient's surgery
D) Step-down to oral fluconazole is not appropriate at this time; the fluid collection adjacent to the anastomotic site with yeast on Gram stain represents likely deep-seated intraabdominal candidiasis — a source of ongoing infection that requires prolonged antifungal therapy and, per IDSA criteria, precludes oral step-down until the deep-seated infection is definitively treated
E) Step-down is appropriate and the total course from the first negative blood culture should be 7 days of oral fluconazole; uncomplicated candidemia in a diabetic patient requires a shorter course than the standard 14 days because hyperglycemia-mediated immune suppression resolves rapidly with glucose control
ANSWER: D
Rationale:
Option D is correct. This patient fails one critical step-down criterion: absence of deep-seated infection. The peri-anastomotic fluid collection with yeast on Gram stain represents probable deep-seated intraabdominal candidiasis — a source of ongoing infection extending beyond the bloodstream. IDSA step-down criteria require that deep-seated infection (endocarditis, osteomyelitis, CNS infection, intraabdominal abscess, or other tissue-invasive disease) be absent before transitioning to oral fluconazole. Intraabdominal candidiasis typically requires prolonged antifungal therapy, often 14 or more days after adequate source control (drainage), and necessitates continued intravenous therapy or confirmation that the site is adequately drained and clinically resolving before step-down. All other criteria in this patient are met — susceptibility confirmed, blood cultures negative, endocarditis excluded, ocular disease excluded, neutropenia resolved — but the deep-seated infection criterion is not satisfied.
Option A: Option A is incorrect: this option overlooks the peri-anastomotic fluid collection with yeast; the presence of probable intraabdominal candidiasis is a specific IDSA step-down exclusion criterion that cannot be disregarded even when other criteria are met.
Option B: Option B is incorrect: oral fluconazole has high bioavailability (>90%) and does not require solid food to achieve adequate absorption; tolerating oral medications and liquids is sufficient for step-down consideration, and solid food intake is not a criterion.
Option C: Option C is incorrect: fluconazole is well absorbed throughout the small bowel, and moderate distal small bowel resection for ischemic bowel does not reliably impair fluconazole bioavailability to a degree that precludes oral therapy; this is not the reason step-down is inappropriate in this case.
Option E: Option E is incorrect: the standard treatment duration for candidemia is 14 days from the last positive blood culture regardless of diabetic status; there is no evidence-based abbreviated course for diabetic patients, and the presence of deep-seated infection in this patient would require an even longer treatment duration.
8. A 49-year-old kidney transplant recipient maintained on sirolimus 3 mg daily (recent trough 9.2 ng/mL, within target range of 5 to 15 ng/mL) develops dysphagia and odynophagia. Upper endoscopy confirms esophageal candidiasis with Candida albicans. Susceptibility is pending. The transplant team starts micafungin 150 mg IV daily. On Day 4, routine sirolimus TDM (therapeutic drug monitoring) returns a trough of 21 ng/mL. Creatinine is stable. Which statement best explains the elevated trough and guides the most appropriate response?
A) The sirolimus elevation reflects acute kidney injury caused by esophageal candidiasis-associated bacteremia; the micafungin dose should be halved to reduce renal competition for tubular sirolimus secretion
B) Micafungin weakly inhibits intestinal CYP3A4 (cytochrome P450 3A4) and possibly P-glycoprotein, increasing sirolimus AUC (area under the concentration-time curve) by approximately 21%; the sirolimus dose should be reduced and TDM repeated in 3 to 5 days, with further adjustment guided by trough concentrations throughout the micafungin course and after its completion
C) The elevated sirolimus trough reflects competitive inhibition of sirolimus renal elimination by micafungin's M-1 catechol metabolite; the appropriate response is to hold sirolimus entirely until micafungin is discontinued and trough concentrations normalize
D) The sirolimus elevation is caused by micafungin displacing sirolimus from plasma protein binding sites, transiently increasing free sirolimus concentrations; since the standard assay measures total sirolimus (bound plus free), the result overestimates toxicity — no dose adjustment is required
E) The elevated trough indicates that this patient is a CYP3A4 poor metabolizer; micafungin has unmasked a pharmacogenomic predisposition to sirolimus accumulation that was previously compensated by adequate enzyme activity; sirolimus should be discontinued and tacrolimus substituted
ANSWER: B
Rationale:
Option B is correct. Micafungin is a weak inhibitor of CYP3A4 primarily at the intestinal level and may also inhibit intestinal P-glycoprotein. Sirolimus is a substrate of both intestinal CYP3A4 and P-glycoprotein; reduced pre-systemic metabolism and efflux by micafungin's inhibitory effect increases sirolimus oral bioavailability, producing an approximately 21% increase in sirolimus AUC. In this patient, the trough has risen from 9.2 ng/mL to 21 ng/mL — a greater-than-doubling that likely reflects both the pharmacokinetic interaction and individual pharmacokinetic variability. Sirolimus has a narrow therapeutic index and supratherapeutic concentrations carry risks of thrombocytopenia, impaired wound healing, pneumonitis, and nephrotoxicity. The appropriate response is to reduce the sirolimus dose, repeat TDM in 3 to 5 days, and continue monitoring throughout the micafungin course. Sirolimus dosing will also need reassessment after micafungin is discontinued, as the inhibitory effect will resolve. Micafungin should not be discontinued solely for this interaction — dose adjustment of sirolimus is the correct management.
Option A: Option A is incorrect: bacteremia is not described, creatinine is stable, and micafungin does not compete with sirolimus for renal tubular secretion; the mechanism described is fabricated.
Option C: Option C is incorrect: micafungin's M-1 metabolite does not inhibit renal sirolimus elimination; sirolimus is primarily eliminated by CYP3A4-mediated hepatic metabolism, not renal tubular secretion, and holding sirolimus entirely without dose adjustment is an overly drastic response to a known and manageable interaction.
Option D: Option D is incorrect: protein binding displacement is not the mechanism of the micafungin-sirolimus interaction; CYP3A4 and P-gp inhibition is the established pharmacokinetic basis, and the interaction is real and clinically meaningful — dose adjustment is required.
Option E: Option E is incorrect: CYP3A4 poor metabolizer status would have manifested as elevated sirolimus troughs before micafungin was started; a previously therapeutic trough of 9.2 ng/mL argues against a pharmacogenomic predisposition as the explanation for the current elevation.
9. An ICU nurse practitioner pages the infectious disease fellow: a patient's blood culture from a central line has grown a yeast preliminarily identified as Candida auris by MALDI-TOF. The patient is a 72-year-old woman with end-stage renal disease on intermittent hemodialysis, receiving voriconazole for presumed aspergillosis that has not been confirmed by culture or galactomannan. She has a femoral central venous catheter placed one week ago. Which integrated set of actions — antifungal selection, susceptibility testing, and infection control — is most appropriate?
A) Continue voriconazole and add fluconazole 800 mg IV loading dose then 400 mg daily; C. auris retains susceptibility to fluconazole in most cases when voriconazole has already been used, and dual azole therapy provides adequate empirical coverage without requiring susceptibility data
B) Switch to fluconazole 800 mg IV loading dose then 400 mg daily as the sole antifungal; the prior voriconazole rules out azole resistance, and fluconazole is the preferred empirical agent for C. auris because its oral bioavailability enables rapid step-down without IV line requirements
C) Start liposomal amphotericin B 5 mg/kg IV daily; C. auris is uniformly resistant to all azoles and all echinocandins, making L-AmB the only active agent; contact precautions are optional because C. auris transmission through environmental surfaces has not been confirmed
D) Continue voriconazole without modification; C. auris is typically susceptible to extended-spectrum triazoles including voriconazole, and the current regimen already provides adequate empirical coverage — susceptibility testing for C. auris is unnecessary if the patient is on an agent with expected activity
E) Start an echinocandin (caspofungin, micafungin, or anidulafungin) immediately; discontinue voriconazole if aspergillosis is not confirmed; send the isolate for formal susceptibility testing because echinocandin-resistant C. auris occurs and assumptions of susceptibility cannot be made; place the patient on contact precautions and notify infection control, as C. auris spreads through environmental contamination and healthcare worker contact and requires active facility-level containment; consider femoral catheter removal given the high-risk site and biofilm risk
ANSWER: E
Rationale:
Option E is correct and integrates four simultaneous imperatives. First, antifungal selection: C. auris has very high rates of fluconazole resistance (typically >90%) and variable rates of polyene resistance; most isolates retain echinocandin susceptibility at time of diagnosis, making echinocandins the preferred empirical agent. Voriconazole, while not universally ineffective against C. auris, is not the preferred empirical agent and should be discontinued if the indication (unconfirmed aspergillosis) is not established. Second, susceptibility testing: C. auris echinocandin resistance mediated by FKS mutations does occur, particularly in isolates with prior echinocandin exposure; formal susceptibility testing is mandatory and cannot be replaced by empirical assumptions. Third, infection control: C. auris is a healthcare-associated pathogen that colonizes patients, survives on environmental surfaces, spreads via healthcare worker hands and contaminated equipment, and has caused nosocomial outbreaks in ICUs globally; contact precautions, patient isolation or cohorting, enhanced environmental disinfection, and immediate notification of infection control are non-negotiable. Fourth, source control: the femoral catheter represents both a nidus for biofilm formation and a high-risk site; removal should be strongly considered.
Option A: Option A is incorrect: dual azole therapy provides no pharmacological advantage and fails to address C. auris's near-universal fluconazole resistance; prior voriconazole does not predict fluconazole susceptibility.
Option B: Option B is incorrect: C. auris has very high rates of fluconazole resistance; using fluconazole empirically for C. auris is pharmacologically inappropriate regardless of prior antifungal exposure.
Option C: Option C is incorrect: C. auris is not uniformly echinocandin-resistant; echinocandin resistance exists but is not universal, and echinocandins are preferred empirically over L-AmB; contact precautions are definitively required and not optional.
Option D: Option D is incorrect: C. auris susceptibility to voriconazole is not reliable enough to continue it as empirical therapy without susceptibility data, and susceptibility testing for C. auris is always required — assumptions of activity based on drug class are not appropriate for this pathogen.
10. A 34-year-old man with acute lymphoblastic leukemia underwent allogeneic stem cell transplantation six weeks ago and developed probable invasive pulmonary aspergillosis (IPA) confirmed by positive serum galactomannan and characteristic CT findings. He was started on voriconazole 4 mg/kg IV twice daily. After three weeks of therapy, he remains febrile, serum galactomannan has risen from 2.1 to 4.8 ODI (optical density index), and repeat CT shows progression of bilateral nodular infiltrates with new cavitation. The team considers adding an echinocandin to voriconazole. Which statement correctly integrates the pharmacological rationale for this combination with the known limitations of echinocandins as IPA monotherapy?
A) Adding an echinocandin is pharmacologically irrational because echinocandins have no activity against Aspergillus at any dose; their mechanism targets a cell wall component absent in Aspergillus species, making any antifungal effect against this pathogen impossible
B) Adding an echinocandin is appropriate only if voriconazole resistance is first confirmed by Aspergillus susceptibility testing; in the absence of confirmed resistance, combination therapy adds toxicity without pharmacological rationale and is not guideline-supported
C) Echinocandins inhibit beta-1,3-d-glucan synthesis at actively growing Aspergillus hyphal tips, producing fungistatic activity that does not kill established hyphae — this precludes echinocandin monotherapy as first-line treatment for IPA; however, the complementary mechanisms of cell wall glucan synthesis inhibition (echinocandin) and ergosterol biosynthesis inhibition (voriconazole) target two independent fungal biosynthetic pathways, providing pharmacological rationale for combination in refractory disease; IDSA guidelines consider this an option in severe or refractory IPA
D) Adding an echinocandin replaces voriconazole as the more active agent for IPA because echinocandins achieve fungicidal activity against Aspergillus in the lung tissue concentrations reached by standard dosing; voriconazole should be discontinued to reduce the cumulative azole toxicity in a post-transplant patient
E) Echinocandins should not be added to voriconazole in this patient because both agents inhibit ergosterol biosynthesis — voriconazole directly and echinocandins by reducing the sterol demand of the cell wall — producing pharmacological redundancy without additive efficacy and increasing the risk of drug-induced hepatotoxicity
ANSWER: C
Rationale:
Option C is correct. Two pharmacological principles must be integrated. First, the limitation: echinocandins produce fungistatic (not fungicidal) activity against Aspergillus by inhibiting beta-1,3-d-glucan synthesis at actively growing hyphal tips. This disrupts new hyphal growth but does not kill existing hyphae, which explains why echinocandin monotherapy is not first-line for IPA — voriconazole or isavuconazole is preferred as primary therapy. Second, the rationale for combination: voriconazole inhibits CYP51 (lanosterol 14-alpha-demethylase) in the ergosterol biosynthesis pathway — a cell membrane target — while echinocandins inhibit beta-1,3-d-glucan synthase — a cell wall synthesis target. These are two independent, essential fungal biosynthetic pathways. Targeting both simultaneously may produce additive or synergistic antifungal effects. In this patient with galactomannan-positive refractory IPA and radiographic progression on voriconazole monotherapy, adding an echinocandin is supported by the complementary mechanism rationale and IDSA guidelines, which consider combination therapy an option in severe or refractory IPA.
Option A: Option A is incorrect: echinocandins do have activity against Aspergillus — fungistatic activity by inhibiting glucan synthesis at hyphal tips; the cell wall of Aspergillus contains beta-1,3-d-glucan, making the drug target present, not absent.
Option B: Option B is incorrect: combination therapy for refractory IPA is supported by IDSA guidelines as an option in refractory disease without requiring prior confirmed resistance; the pharmacological rationale for combination is independent of voriconazole MIC.
Option D: Option D is incorrect: echinocandins are fungistatic, not fungicidal, against Aspergillus and should not replace voriconazole as the primary agent; discontinuing voriconazole in favor of an echinocandin would represent a step backward in IPA management.
Option E: Option E is incorrect: echinocandins and azoles have entirely different mechanisms — cell wall glucan synthesis inhibition versus ergosterol membrane biosynthesis inhibition; they do not share a mechanism of action, there is no pharmacological redundancy, and cell wall glucan inhibition does not reduce ergosterol demand.
11. A 78 kg, 58-year-old man with alcoholic cirrhosis (Child-Pugh score 8) is admitted with Candida albicans candidemia. The covering intern writes the following caspofungin order: "Caspofungin 50 mg IV once daily — start today." The clinical pharmacist reviewing the order identifies two separate dosing errors. Which description correctly identifies both errors and states the pharmacologically correct regimen?
A) One error is present: the loading dose is omitted; the 50 mg maintenance dose is correct because caspofungin is not metabolized by CYP enzymes and therefore requires no adjustment for hepatic impairment; the correct regimen is 70 mg IV loading dose on Day 1 then 50 mg IV once daily
B) Two errors are present: (1) the loading dose is omitted; (2) the maintenance dose requires reduction for Child-Pugh class B impairment, but to 25 mg IV once daily; the correct regimen is 70 mg IV loading dose on Day 1 then 25 mg IV once daily
C) One error is present: the loading dose is omitted; the 50 mg maintenance dose is correct because Child-Pugh class B impairment does not require dose adjustment — only Child-Pugh class C (score above 9) mandates reduction; the correct regimen is 70 mg loading dose on Day 1 then 50 mg once daily
D) Two errors are present: (1) the loading dose is omitted; (2) the route should be changed to intramuscular injection in a patient with cirrhosis to avoid hepatic first-pass metabolism; the correct regimen is 70 mg IM on Day 1 then 50 mg IM once daily
E) Two errors are present: (1) the loading dose is omitted — without 70 mg IV on Day 1, steady-state plasma concentrations will be delayed by approximately two weeks given caspofungin's terminal half-life of 40 to 50 hours; (2) the 50 mg maintenance dose is incorrect for this patient's hepatic impairment — Child-Pugh score 8 (class B) requires reduction to 35 mg IV once daily; the correct regimen is 70 mg IV loading dose on Day 1, then 35 mg IV once daily thereafter
ANSWER: E
Rationale:
Option E is correct. Two distinct dosing errors are present in this order. Error 1 — loading dose omission: caspofungin has a terminal elimination half-life of approximately 40 to 50 hours; without the 70 mg loading dose on Day 1, steady-state plasma concentrations would not be achieved for approximately two weeks, an unacceptable delay for active candidemia. Error 2 — hepatic impairment dose adjustment: Child-Pugh score 8 falls in the class B (moderate) impairment range (scores 7 to 9); the approved caspofungin maintenance dose in moderate hepatic impairment is reduced from 50 mg to 35 mg once daily, while the 70 mg loading dose is retained. The correct regimen is therefore a 70 mg IV loading dose on Day 1 followed by 35 mg IV once daily. Note that weight-based escalation to 70 mg maintenance is reserved for adult patients weighing more than 80 kg; at 78 kg this patient does not meet the weight threshold, so no weight-based adjustment applies and the hepatic reduction is the only maintenance-dose modification required. (When both a weight above 80 kg and moderate hepatic impairment coexist in the same patient, the prescribing information does not specify how to reconcile the competing 70 mg and 35 mg recommendations, and that ambiguous situation is deliberately avoided here.)
Option A: Option A is incorrect: although caspofungin is not a CYP substrate, it still requires a maintenance dose reduction in moderate hepatic impairment (Child-Pugh 7 to 9), because hepatic dysfunction reduces caspofungin clearance through its N-acetylation and hydrolysis pathways. Identifying only the missing loading dose misses the required hepatic adjustment.
Option B: Option B correctly identifies both the missing loading dose and the need for a hepatic reduction, but states the wrong target dose: the approved Child-Pugh class B maintenance dose is 35 mg once daily, not 25 mg. There is no 25 mg caspofungin maintenance recommendation.
Option C: Option C is incorrect: it identifies only one error and incorrectly claims that only Child-Pugh class C requires adjustment. Child-Pugh 7 to 9 (class B, moderate impairment) is the established threshold for reducing the caspofungin maintenance dose to 35 mg; class C (score above 9) is the range in which caspofungin is generally avoided owing to limited data.
Option D: Option D is incorrect: caspofungin is an intravenous formulation only; intramuscular administration is not an approved route and is not used to avoid hepatic first-pass metabolism for an IV drug. It also omits the required hepatic maintenance-dose reduction.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.